Sanofi India Recovers: Q1'26 Revenue Surges 32%, FY25 Profit ₹240 Crore

Revenue and Profit Highlights

Sanofi India's consumer healthcare segment reported a significant 32.06% year-on-year revenue increase for the quarter ended March 31, 2026, reaching ₹2,348 million. For the full year ended December 31, 2025, the company recorded a standalone profit of ₹2,401 million (₹240.10 crore).

Recovery Driven by Brand Relaunches

This revenue growth signals a strong recovery following product recalls in 2024. The company's strategy of relaunching major brands, including Allegra, Combiflam, and Depura Kids, has successfully stabilized operations and is driving current growth.

Financial Context and Rising Costs

Sanofi India's total standalone revenue for fiscal year 2025 (ended December 31, 2025) was ₹8,968 million. However, the company recognized an incremental expense of ₹24 million in 2025. This cost is related to employee benefit expenses resulting from the implementation of new labor codes.

Market Standing and Investor Focus

The strong financial performance suggests Sanofi India is regaining market traction. While previous year data might be complicated by voluntary product recalls, the relaunched brands are expected to continue contributing to revenue and market share. Investors will monitor sustained revenue growth, the performance of relaunched brands against competitors, and management commentary on margin outlook amidst rising costs.